Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.10
ULGX's Cash to Debt is ranked lower than
68% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. ULGX: 0.10 )
ULGX' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.1

Equity to Asset -1.45
ULGX's Equity to Asset is ranked lower than
73% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ULGX: -1.45 )
ULGX' s 10-Year Equity to Asset Range
Min: -1.45   Max: 0.96
Current: -1.45

-1.45
0.96
F-Score: 2
Z-Score: -34.65
M-Score: -7.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -41.18
ULGX's Operating margin (%) is ranked lower than
71% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. ULGX: -41.18 )
ULGX' s 10-Year Operating margin (%) Range
Min: -1950   Max: 12.1
Current: -41.18

-1950
12.1
Net-margin (%) -46.93
ULGX's Net-margin (%) is ranked lower than
71% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ULGX: -46.93 )
ULGX' s 10-Year Net-margin (%) Range
Min: -1900   Max: 21.22
Current: -46.93

-1900
21.22
ROA (%) -81.65
ULGX's ROA (%) is ranked lower than
68% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ULGX: -81.65 )
ULGX' s 10-Year ROA (%) Range
Min: -83.63   Max: 13.24
Current: -81.65

-83.63
13.24
ROC (Joel Greenblatt) (%) -1133.91
ULGX's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. ULGX: -1133.91 )
ULGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -498.38   Max: 72.25
Current: -1133.91

-498.38
72.25
Revenue Growth (3Y)(%) -8.00
ULGX's Revenue Growth (3Y)(%) is ranked lower than
94% of the 346 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. ULGX: -8.00 )
ULGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -20.9   Max: 108
Current: -8

-20.9
108
EBITDA Growth (3Y)(%) 10.90
ULGX's EBITDA Growth (3Y)(%) is ranked lower than
109% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ULGX: 10.90 )
ULGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -80.1   Max: 17
Current: 10.9

-80.1
17
EPS Growth (3Y)(%) 11.50
ULGX's EPS Growth (3Y)(%) is ranked lower than
105% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ULGX: 11.50 )
ULGX' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.1   Max: 11.9
Current: 11.5

-54.1
11.9
» ULGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ULGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.13
ULGX's P/S is ranked lower than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.68 vs. ULGX: 0.13 )
ULGX' s 10-Year P/S Range
Min: 0.09   Max: 9.56
Current: 0.13

0.09
9.56
EV-to-EBIT -1.27
ULGX's EV-to-EBIT is ranked lower than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 73.27 vs. ULGX: -1.27 )
ULGX' s 10-Year EV-to-EBIT Range
Min: -11057.7   Max: 430.2
Current: -1.27

-11057.7
430.2
Current Ratio 0.70
ULGX's Current Ratio is ranked lower than
69% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ULGX: 0.70 )
ULGX' s 10-Year Current Ratio Range
Min: 0.7   Max: 24.53
Current: 0.7

0.7
24.53
Quick Ratio 0.44
ULGX's Quick Ratio is ranked lower than
69% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. ULGX: 0.44 )
ULGX' s 10-Year Quick Ratio Range
Min: 0.44   Max: 24.29
Current: 0.44

0.44
24.29
Days Inventory 66.28
ULGX's Days Inventory is ranked lower than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 166.67 vs. ULGX: 66.28 )
ULGX' s 10-Year Days Inventory Range
Min: 54.36   Max: 277.9
Current: 66.28

54.36
277.9
Days Sales Outstanding 42.60
ULGX's Days Sales Outstanding is ranked lower than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.87 vs. ULGX: 42.60 )
ULGX' s 10-Year Days Sales Outstanding Range
Min: 34.05   Max: 130.36
Current: 42.6

34.05
130.36

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.13
ULGX's Price/Median PS Value is ranked lower than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ULGX: 0.13 )
ULGX' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 150
Current: 0.13

0.1
150
Earnings Yield (Greenblatt) -88.60
ULGX's Earnings Yield (Greenblatt) is ranked lower than
69% of the 468 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ULGX: -88.60 )
ULGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 3169.7
Current: -88.6

0.2
3169.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Urologix Inc was incorporated in Minnesota. The Company develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use proprietary technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. It acquired the license to the Prostiva RF Therapy System in September 2011. These two technologies are designed to be used by urologists in their offices without placing their patients under general anesthesia. CTT uses a flexible catheter to deliver targeted microwave energy combined with a unique cooling mechanism that protects healthy urethral tissue and enhances patient comfort to provide safe, effective, lasting relief from BPH voiding symptoms by the thermal ablation of hyperplastic prostatic tissue surrounding the urethra. The proprietary Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. These two proven technologies have slightly different, yet complementary, patient indications and providing them to its urologist customers enables them to treat a various patients in their office. Both domestic and international government regulation significantly affects the research and development, manufacturing and marketing of its products.
» More Articles for ULGX

Headlines

Articles On GuruFocus.com
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares Feb 01 2011 
Urologix Inc. Reports Operating Results (10-K) Sep 17 2010 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares Dec 09 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares Dec 07 2009 
Urologix Inc. Reports Operating Results (10-K) Sep 21 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,870 Shares Sep 03 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,635 Shares Aug 31 2009 
Urologix Reports Fiscal 2009 Results Including Sequential Growth in Fourth Quarter Fiscal Year 2009 Aug 25 2009 
Urologix to Host Its Fiscal Year 2009 and Fourth Quarter Conference Call Aug 19 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,495 Shares May 29 2009 

More From Other Websites
UROLOGIX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Mar 23 2015
Urologix Announces Hiring of Chief Financial Officer Mar 23 2015
Urologix Announces Hiring of Chief Financial Officer Mar 23 2015
UROLOGIX INC Financials Feb 20 2015
10-Q for Urologix, Inc. Feb 15 2015
UROLOGIX INC Files SEC form 10-Q, Quarterly Report Feb 13 2015
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 06 2015
Urologix Inc Earnings Call scheduled for 5:00 pm ET today Feb 05 2015
Urologix Reports Second Quarter Fiscal Year 2015 Results Feb 05 2015
Q2 2015 Urologix Inc Earnings Release - After Market Close Feb 05 2015
Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call Jan 29 2015
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events Jan 12 2015
Urologix Reports Preliminary Fiscal Year 2015 Second Quarter Revenue and Cash Results Jan 12 2015
OTC Markets Group Welcomes Urologix to OTCQB Dec 02 2014
UROLOGIX INC Files SEC form 10-Q, Quarterly Report Nov 13 2014
UROLOGIX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 05 2014
Urologix Reports First Quarter Fiscal Year 2015 Results Nov 04 2014
Urologix to Host Its Fiscal Year 2015 First Quarter Conference Call Oct 28 2014
UROLOGIX INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK